Ozarelix - CISMeF

Preferred Label : Ozarelix;

NCIt synonyms : LHRH antagonist SPI-153;

NCIt definition : A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.;

UNII : Q1IF8M2YL3;

InChIKey : KATZUZNTRINHDT-HALMFYTRSA-N;

CAS number : 295350-45-7;

Molecule name : D-63 153; SPI-153; D 63153; D63153;

Détails

Origin ID

C95214;

UMLS CUI

C2987000;

Currated CISMeF NLP mapping
- ozarelix [MeSH concept]
- ozarelix [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- ozarelix [MeSH Supplementary Concept]
- ozarelix [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients